

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
June 20, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

June 20 2007

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b): 82-\_\_\_\_\_

TRANSACTION IN OWN SHARES

REDUCTION OF THE SHARE CAPITAL AND HOLDING OF OWN SHARES (19 JUNE 2007)

At Novo Nordisk's ordinary general meeting on the 7 March 2007 it was decided to  
reduce the company's B-share capital from DKK 566,432,800 to DKK 539,472,800 by  
cancellation of part of the company's portfolio of own B shares at a nominal  
value of DKK 26,960,000 divided into 13,480,000 B shares of DKK 2 each.

## Edgar Filing: NOVO NORDISK A S - Form 6-K

Today, Novo Nordisk has registered the final implementation of the reduction of the share capital with the Danish Commerce and Companies Agency and cancelled nominally DKK 26,960,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 646,960,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 539,472,800.

### HOLDING OF OWN SHARES

In the company's stock exchange announcement no 8/2007 of 3 April 2007 it was stated that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates as per 31 March 2007 owned 19,163,309 of its own B shares of DKK 2, corresponding to a total nominal value of DKK 38,326,618 or 5.69% of the total share capital.

Since 3 April 2007 a total of 138,000 B shares have been repurchased by Novo Nordisk A/S, and 306,625 B shares have been disposed of to employees who have exercised options granted by Novo Nordisk.

Following the cancellation of nominally DKK 26,960,000 (13,480,000 shares) of the company's own B shares and pursuant to Section 28 of the Danish securities Trading Act, it is hereby announced that Novo Nordisk A/S and its wholly-owned affiliates as per 19 June 2007 own 5,514,684 of its own B shares. This corresponds to a total nominal value of DKK 11,029,368 B-shares or 1.7% of the total share capital.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 23.600 full-time employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

### Further information:

#### Media:

#### Outside North America:

Elin K Hansen  
Tel: (+45) 4442 3450  
[ekh@novonordisk.com](mailto:ekh@novonordisk.com)

#### Investors:

#### Outside North America:

Mads Veggerby Lausten  
Tel: (+45) 4443 7919  
[mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Hans Rommer

Tel: (+45) 4442 4765  
[hrrmm@novonordisk.com](mailto:hrrmm@novonordisk.com)

#### In North America:

Lori Moore  
Tel: (+1) 609 919 7991  
[lrmo@novonordisk.com](mailto:lrmo@novonordisk.com)

#### In North America:

Christian Qvist Frandsen  
Tel: (+1) 609 919 7937  
[cqfr@novonordisk.com](mailto:cqfr@novonordisk.com)

Stock Exchange Announcement no 16 / 2007

SIGNATURES

Edgar Filing: NOVO NORDISK A S - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 20 2007

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer